Valsts: Īrija
Valoda: angļu
Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)
ABCIXIMAB
Janssen Biologics B.V.
B01AC13
ABCIXIMAB
2 Mg/Ml
Solution for Inj/Inf
Product subject to prescription which may not be renewed (A)
Platelet aggregation inhibitors excl. Heparin
Authorised
1995-07-12
PACKAGE LEAFL ET: INFORMATION FOR THE USER REOPRO ® 2 MG/ML SOLUTION FOR INJECTION OR INFUSION abciximab READ ALL OF THIS LEAFL ET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leafl et. You may need to read it again. - If you have further questions, ask your doctor. - If you get any of side eff ects, talk to your doctor. This includes any possible side eff ects not listed in this leafl et. See section 4. WHAT IS IN THIS LEAFL ET 1. WHAT REOPRO IS AND WHAT IT IS USED FOR 2. WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN REOPRO 3. HOW TO USE REOPRO 4. POSSIBLE SIDE EFF ECTS 5. HOW TO STORE REOPRO 6. CONTENTS OF THE PACK AND OTHER INFORMATION 1. WHAT REOPRO IS AND WHAT IT IS USED FOR WHAT REOPRO IS? The active ingredient, abciximab, is a ‘murine monoclonal antibody’. Monoclonal antibodies are proteins that recognise and bind to other unique proteins. ReoPro belongs to a group of medicines known as antithrombotics and binds to proteins in your blood to help to prevent blood clots. WHAT IS REOPRO USED FOR? ReoPro is used when you undergo an operation known as angioplasty (see “What is an angioplasty operation?” below) for the following purposes: • ReoPro is used (together with heparin and acetylsalicylic acid) to prevent the formation of blood clots in the heart during or after an angioplasty operation. • ReoPro is also used (together with heparin and acetylsalicylic acid) to lower the short term risk of getting a heart attack before an angioplasty operation, which is planned to take place within the next 1-month. This is for patients who have chest pain due to low blood supply to the heart (unstable angina) and have not responded to the usual therapy. WHAT IS AN ANGIOPLASTY OPERATION? An angioplasty operation aims to open blocked arteries around the heart. A doctor will carefully guide a special instrument through an artery (whi Izlasiet visu dokumentu
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT ReoPro 2 mg/mL solution for injection or infusion. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ReoPro 2 mg/mL contains 10 mg abciximab in 5 mL water for injection. Abciximab is the Fab fragment of a chimeric IgG1 monoclonal antibody manufactured from a recombinant cell line cultured by continuous perfusion. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection or infusion ReoPro is a colourless and clear liquid. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS ReoPro is indicated in adults as an adjunct to heparin and acetylsalicylic acid for: • Percutaneous coronary intervention The prevention of ischemic cardiac complications in patients undergoing percutaneous coronary intervention (balloon angioplasty, atherectomy and stent) (see section 5.1) • Unstable angina The short-term (1-month) reduction of the risk of myocardial infarction, in patients with unstable angina, not responding to full conventional therapy who have been scheduled for percutaneous coronary intervention. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Adults The recommended dose of ReoPro is a 0.25 mg/kg intravenous bolus immediately followed by a 0.125 µg/kg/min (to a maximum of 10 µg/min) continuous intravenous infusion. For the stabilisation of unstable angina patients, the bolus dose followed by the infusion should be started up to 24 hours prior to the possible intervention and concluded 12 hours after the intervention. For the prevention of ischemic cardiac complications in patients undergoing percutaneous coronary intervention, and who are not currently receiving a ReoPro infusion, the bolus should be administered 10 to 60 minutes prior to the intervention followed by the infusion for 12 Izlasiet visu dokumentu